

RUSH Institutional Biosafety Committee (IBC)	
Meeting Date	January 21, 2026
Meeting Time	12:00 PM – 1:00 PM
Meeting Type	Virtual via Microsoft Teams
IBC Members Present	<ol style="list-style-type: none"> 1. Amarjit Viridi, Ph.D. (IBC Chair) 2. Ed R. Blazek, Ph.D., SM (NRCM) (BSO) 3. James Bremer, Ph.D. (IBC Member / Virology) 4. João Mamede, Ph.D. (IBC Member / Recombinant DNA Technologies) 5. Rebecca ‘Bex’ Ober, D.V.M. (Senior Director, Comparative Research Center) 6. Liudmila Romanova, Ph.D. (IBC Member / Expertise Neurological Sciences) 7. Jennifer Strong (<i>ex officio</i> Non-Voting / Research Compliance)
Quorum	<p>Quorum was declared by the Chair.</p> <p>The IBC has nine voting members, and five members are required to conduct business.</p>
Other Individuals in Attendance	<ol style="list-style-type: none"> 1. Christine VanTubbergen, MPH (Program Manager, Office of Research Affairs)
Call to Order	The IBC Chair called the meeting to order at 12:02 PM.
Conflicts of Interest	The IBC Chair reminded all members present to identify any conflicts of interest as each application is reviewed.
Review and Approval of Previous Meeting Minutes	<p>November 19, 2025</p> <p>Motion: Approve the minutes as circulated.</p> <p>Votes: 6-0-0-0 (for-against-abstain-recuse)</p>

Review of Prior Business		
PI Name & ORA #	Application	Approval Date
Berry-Kravis, Elizabeth, M.D. 25032404-IBC03	Amendment 02	11/21/2025
Berry-Kravis, Elizabeth, M.D. 24021304-IBC11	Amendment 09	11/24/2025
Nathan, Sunita, M.D. 19070910-IBC22	Continuing Review 07	11/25/2025
Kelta, Mouhammed, M.D. 23081106-IBC08	Amendment 06	11/25/2025
Reisz, Peter, M.D. 23082101-IBC09	Amendment 07	11/26/2025
Miller, Ira, M.D. 22070504-IBC02	Initial Application	11/28/2025
Gupta, Kajal, Ph.D. 23072802-IBC01	Initial Application	Withdrawn 12/01/2025
Oh, Chundo, Ph.D. 20100507-IBC01	Initial Application	Withdrawn 12/01/2025
O’Toole, John, M.D. 28081203-IBC01	Initial Application	Withdrawn 12/02/2025
Simpson, Mindy, M.D. 23110201-IBC01	Initial Application	12/04/2025
Huang, Jian, Ph.D. 15092803-IBC01	Initial Application	Closed 12/05/2025
Berry-Kravis, Elizabeth, M.D. 24090903-IBC07	Continuing Review 01	12/05/2025
Berry-Kravis, Elizabeth, M.D. 24021304-IBC12	Amendment 10	12/15/2025

Hall, Deborah, M.D. 19010804-IBC30	Amendment 35	12/22/2025
Nathan, Sunita, M.D. 24061205-IBC08	Continuing Review 01	12/29/2025
Wang, Yanling, Ph.D. 18100106-IBC11	Amendment 10	01/14/2026
Wang, Yanling, Ph.D. 21110104-IBC03	Amendment 01	01/15/2026
Westbrook, Thomas, M.D. 24032202-IBC06	Amendment 05	01/21/2026

New IBC Applications for Review	
PI Name	Romanova, Liudmila, Ph.D.
ORA#	25011308-IBC01
Project Overview	III-D-3 This study aims to generate immortalized rat and human arachnoid cell lines for use in subsequent <i>in vitro</i> work studying barrier transport and integrity in Alzheimer's disease. Retroviral vectors will be utilized to transfer genes into primary cell lines.
NIH Guidelines Section	III-D-3
Risk Assessment & Discussion	<ul style="list-style-type: none"> • The retroviral vectors are a RG-2 agents. • A biological safety cabinet (BSC) will be utilized. • PPE consisting of lab coat, gloves, surgical mask, and eye protection will be utilized. • Whole animals will not be utilized for this study, only cells. • Waste disposal methods were not described within the application.
Training	<p>For research requiring IBC oversight, the PI must complete the CITI Initial Biosafety Training course and clinical lab personnel must complete the CITI Basic Biosafety Training course.</p> <p>For research involving human gene transfer, the PI and personnel must complete either the CITI Recombinant Clinical Biosafety Course or the CITI Recombinant Clinical Coordinator course, depending on research activity involvement.</p> <p>At least one individual has current CITI International Air and Transportation Association (IATA) training.</p>
Occupational Health Representative Review (if applicable)	Not applicable.
BSL Assignment	<ul style="list-style-type: none"> • BSL-2
IBC Vote	<ul style="list-style-type: none"> • A motion was made to provisionally approve this application pending the following conditions be met: <ul style="list-style-type: none"> • Completion of biosafety training for all personnel • Addition of waste disposal methods • Description of how immortalized cell lines will be utilized • Description of how tissues will be obtained <p><u>Votes:</u></p> <ul style="list-style-type: none"> • 5-0-0-0 <p>Conflicts of Interest: The PI for this study also serves as a voting member of the IBC. This individual left the meeting after a study summary was provided, prior to discussion and voting. This individual rejoined the meeting once voting was complete.</p>

New IBC Applications for Review	
PI Name	Tammineni, Eshwar Reddy, Ph.D.
ORA#	25011601-IBC01
Project Overview	III-D-4 This study will transduce mice with AAV9 vectors containing human genes involved

	in glycogen metabolism to understand causes of muscle insulin resistance in Type 2 diabetes.
NIH Guidelines Section	III-D-4
Risk Assessment & Discussion	<ul style="list-style-type: none"> • Adeno-associated virus (AAV) is a RG-1 agent. • A biological safety cabinet (BSC) will be utilized. • PPE consisting of lab coat, gloves, eye protection, and head cover will be utilized. • Liquid waste will be subject to chemical disinfection prior to disposal. Solid wastes (e.g., disposable plasticware) will be disposed of as biohazardous waste.
Training	<p>For research requiring IBC oversight, the PI must complete the CITI Initial Biosafety Training course and clinical lab personnel must complete the CITI Basic Biosafety Training course.</p> <p>For research involving human gene transfer, the PI and personnel must complete either the CITI Recombinant Clinical Biosafety Course or the CITI Recombinant Clinical Coordinator course, depending on research activity involvement.</p> <p>At least one individual has current CITI International Air and Transportation Association (IATA) training.</p>
Occupational Health Representative Review (if applicable)	Not applicable.
BSL Assignment	<ul style="list-style-type: none"> • BSL-2
IBC Vote	<ul style="list-style-type: none"> • A motion was made to table this application, requesting more information and clarification on the study regarding study personnel, number of animal subjects, vector maps, origin of vectors, core facility affidavits, etc. and completion of biosafety training for all personnel and laboratory inspection. <p><u>Votes:</u></p> <ul style="list-style-type: none"> • 6-0-0-0 <p>Conflicts of Interest: None</p>

New Business	Nothing to report.
Review of Incidents	Nothing to report.
Inspections/Ongoing Oversight	Nothing to report.
IBC Training	<p>Two meeting attendees commented that they attempted to join the scheduled 01/15/26 live broadcast of the Strengthening and Modernizing Biosafety Oversight: Region 3 (Midwest) Listening Session, but that the program was not active at this site. These persons had successfully joined a previous listening session.</p> <ul style="list-style-type: none"> • https://osp.od.nih.gov/events/strengthening-and-modernizing-biosafety-oversight-region-3-listening-session/
Public Comments	There were no public comments.
Adjournment	<p>The IBC Chair moved to adjourn the meeting at 12:45 PM</p> <p>The next meeting scheduled is for February 25, 2026 at 12:00 PM via Microsoft Teams.</p>